TY - JOUR
T1 - Sorafenib vs. lenvatinib as first-line therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis
AU - Kuzuya, Teiji
AU - Ishigami, Masatoshi
AU - Ito, Takanori
AU - Ishizu, Yoji
AU - Honda, Takashi
AU - Ishikawa, Tetsuya
AU - Fujishiro, Mitsuhiro
N1 - Publisher Copyright:
© 2020 International Institute of Anticancer Research. All rights reserved.
PY - 2020/4
Y1 - 2020/4
N2 - Background/Aim: We aimed to compare the outcomes between sorafenib and lenvatinib as first-line therapy for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (Vp3/4). Patients and Methods: This retrospective study enrolled 41 HCC patients with Vp3/4 and Child-Pugh A. Results: The outcomes in the lenvatinib group (n=13) were significantly better than those in the sorafenib group (n=28) [best objective response rate according to the modified Response Evaluation Criteria in Solid Tumors: 53.8% vs. 14.3%; p=0.0193, best disease control rate: 92.3% vs. 35.7%; p=0.0008, median overall survival (OS): not reached vs. 187 days; p=0.0040, respectively]. Lenvatinib treatment was the only significant predictor of better OS and time to tumor progression. No patient needed to discontinue lenvatinib treatment due to drug-related adverse events. Conclusion: Compared with sorafenib, lenvatinib treatment for advanced HCC with Vp3/4 may lead to more favorable outcomes.
AB - Background/Aim: We aimed to compare the outcomes between sorafenib and lenvatinib as first-line therapy for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (Vp3/4). Patients and Methods: This retrospective study enrolled 41 HCC patients with Vp3/4 and Child-Pugh A. Results: The outcomes in the lenvatinib group (n=13) were significantly better than those in the sorafenib group (n=28) [best objective response rate according to the modified Response Evaluation Criteria in Solid Tumors: 53.8% vs. 14.3%; p=0.0193, best disease control rate: 92.3% vs. 35.7%; p=0.0008, median overall survival (OS): not reached vs. 187 days; p=0.0040, respectively]. Lenvatinib treatment was the only significant predictor of better OS and time to tumor progression. No patient needed to discontinue lenvatinib treatment due to drug-related adverse events. Conclusion: Compared with sorafenib, lenvatinib treatment for advanced HCC with Vp3/4 may lead to more favorable outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85082732148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082732148&partnerID=8YFLogxK
U2 - 10.21873/anticanres.14193
DO - 10.21873/anticanres.14193
M3 - Article
C2 - 32234927
AN - SCOPUS:85082732148
SN - 0250-7005
VL - 40
SP - 2283
EP - 2290
JO - Anticancer research
JF - Anticancer research
IS - 4
ER -
